Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0UQ2X
|
||||
Former ID |
DIB020332
|
||||
Drug Name |
metergoline
|
||||
Synonyms |
liserdol; metergoline phenylmethyl ester; FI-6337
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Discovery agent | Investigative | [1] | ||
Structure |
![]() |
Download2D MOL |
|||
Formula |
C25H29N3O2
|
||||
InChI |
InChI=1S/C25H29N3O2/c1-27-14-18(13-26-25(29)30-16-17-7-4-3-5-8-17)11-21-20-9-6-10-22-24(20)19(12-23(21)27)15-28(22)2/h3-10,15,18,21,23H,11-14,16H2,1-2H3,(H,26,29)/t18-,21+,23+/m0/s1
|
||||
InChIKey |
WZHJKEUHNJHDLS-QTGUNEKASA-N
|
||||
PubChem Compound ID | |||||
PubChem Substance ID |
855801, 8170546, 10321618, 11466392, 11467512, 11486144, 14781460, 17405287, 22391564, 24263003, 24278105, 26751517, 26751518, 34671115, 46488055, 47721691, 47944884, 47944885, 48170512, 48244474, 48244475, 48319566, 49698459, 49899474, 50104076, 50104077, 50104078, 50558890, 51091556, 53777832, 53790927, 56311628, 56422452, 57310695, 81093356, 85231339, 85788313, 88837624, 90341228, 92125453, 92304154, 93576764, 99445342, 103183978, 103914106, 104171342, 104303418, 117580377, 121361458, 121363124
|
||||
Target and Pathway | |||||
Target(s) | 5-hydroxytryptamine 2C receptor | Target Info | Antagonist | [2] | |
5-hydroxytryptamine 1B receptor | Target Info | Antagonist | [3] | ||
5-hydroxytryptamine 1E receptor | Target Info | Antagonist | [4] | ||
5-hydroxytryptamine 1F receptor | Target Info | Antagonist | [5] | ||
5-hydroxytryptamine 5A receptor | Target Info | Antagonist | [6] | ||
5-hydroxytryptamine 1D receptor | Target Info | Antagonist | [7] | ||
5-hydroxytryptamine 7 receptor | Target Info | Antagonist | [8] | ||
5-hydroxytryptamine 2B receptor | Target Info | Antagonist | [2] | ||
5-hydroxytryptamine 2A receptor | Target Info | Antagonist | [2] | ||
5-hydroxytryptamine 6 receptor | Target Info | Antagonist | [9] | ||
KEGG Pathway | Calcium signaling pathway | ||||
Neuroactive ligand-receptor interaction | |||||
Gap junction | |||||
Serotonergic synapse | |||||
Inflammatory mediator regulation of TRP channelshsa04024:cAMP signaling pathway | |||||
Serotonergic synapsehsa04024:cAMP signaling pathway | |||||
Serotonergic synapsehsa04020:Calcium signaling pathway | |||||
Serotonergic synapsehsa04014:Ras signaling pathway | |||||
Inflammatory mediator regulation of TRP channelshsa04020:Calcium signaling pathway | |||||
cAMP signaling pathway | |||||
PANTHER Pathway | 5HT2 type receptor mediated signaling pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
5HT1 type receptor mediated signaling pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||||
5HT1 type receptor mediated signaling pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||||
5HT1 type receptor mediated signaling pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathwayP04374:5HT2 type receptor mediated signaling pathwayP04374:5HT2 type receptor mediated signaling pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||||
PathWhiz Pathway | Excitatory Neural Signalling Through 5-HTR 7 and SerotoninPW000444:Excitatory Neural Signalling Through 5-HTR 6 and Serotonin | ||||
Reactome | Serotonin receptors | ||||
G alpha (q) signalling eventsR-HSA-390666:Serotonin receptors | |||||
G alpha (i) signalling eventsR-HSA-390666:Serotonin receptors | |||||
G alpha (s) signalling eventsR-HSA-390666:Serotonin receptors | |||||
G alpha (s) signalling events | |||||
WikiPathways | Serotonin Receptor 2 and ELK-SRF/GATA4 signaling | ||||
Monoamine GPCRs | |||||
GPCRs, Class A Rhodopsin-like | |||||
Gastrin-CREB signalling pathway via PKC and MAPK | |||||
GPCR ligand binding | |||||
GPCR downstream signalingWP722:Serotonin HTR1 Group and FOS Pathway | |||||
GPCR downstream signaling | |||||
GPCRs, OtherWP58:Monoamine GPCRs | |||||
GPCR downstream signalingWP734:Serotonin Receptor 4/6/7 and NR3C Signaling | |||||
GPCRs, OtherWP732:Serotonin Receptor 2 and ELK-SRF/GATA4 signaling | |||||
GPCR downstream signalingWP733:Serotonin Receptor 2 and STAT3 Signaling | |||||
SIDS Susceptibility Pathways | |||||
GPCRs, OtherWP734:Serotonin Receptor 4/6/7 and NR3C Signaling | |||||
References | |||||
REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 133). | ||||
REF 2 | Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23. Epub 2004 Jul 30. | ||||
REF 3 | Two amino acid differences in the sixth transmembrane domain are partially responsible for the pharmacological differences between the 5-HT1D beta and 5-HT1E 5-hydroxytryptamine receptors. J Neurochem. 1996 Nov;67(5):2096-103. | ||||
REF 4 | Molecular cloning and pharmacological characterization of the guinea pig 5-HT1E receptor. Eur J Pharmacol. 2004 Jan 26;484(2-3):127-39. | ||||
REF 5 | Cloning and characterization of the guinea pig 5-HT1F receptor subtype: a comparison of the pharmacological profile to the human species homolog. Neuropharmacology. 1997 Apr-May;36(4-5):569-76. | ||||
REF 6 | Cloning and characterisation of the human 5-HT5A serotonin receptor. FEBS Lett. 1994 Dec 5;355(3):242-6. | ||||
REF 7 | Primary structure and functional characterization of a human 5-HT1D-type serotonin receptor. Mol Pharmacol. 1991 Aug;40(2):143-8. | ||||
REF 8 | Cloning of a novel human serotonin receptor (5-HT7) positively linked to adenylate cyclase. J Biol Chem. 1993 Nov 5;268(31):23422-6. | ||||
REF 9 | The 5-hydroxytryptamine6 receptor-selective radioligand [3H]Ro 63-0563 labels 5-hydroxytryptamine receptor binding sites in rat and porcine striatum. Mol Pharmacol. 1998 Sep;54(3):577-83. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.